Johnson & Johnson has a strong business, several growth opportunities, and a safe dividend. The company does face headwinds, but it should be able to overcome them. Some might describe Johnson ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However ...

Johnson & Johnson is acquiring biopharmaceutical company Intra-Cellular Therapies for $14.6 billion. It has an approved depression and schizophrenia treatment that could generate $5 billion in ...

Some might describe Johnson & Johnson's business as boring, but sometimes, that's not such a bad thing. Selling pharmaceutical products is a steady and reliable business even when the economy is ...

High-rolling investors have positioned themselves bearish on Johnson & Johnson JNJ, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga ...

It’s nearly a year and a half since Johnson & Johnson split off its consumer-health arm to focus on pharmaceuticals and medical technology. Johnson & Johnson has wasted no time expanding its ...

The purchase will allow Johnson & Johnson to delve further into the treatment of central nervous system disorders. The purchase is one of several transactions in recent years to boost its ...

Raritan Valley Community College, Middlesex College and Mercer County Community College have joined with Johnson & Johnson to create the initiative. Johnson & Johnson is giving $1 million to the ...

Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the ...

Gabby Jones / Bloomberg / Getty Images Johnson & Johnson is scheduled to report fourth-quarter earnings Wednesday morning, with analysts expecting sales and profits to grow year-over-year.

Johnson & Johnson said Monday it expects to accelerate sales growth beyond Wall Street expectations in the field of neuroscience with the $14.6 billion acquisition of Intra-Cellular Therapies Inc ...